Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHLW Suspends Mitsubishi Tanabe Operations For Fabricating Data

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Ministry of Health, Labor and Welfare has suspended Mitsubishi Tanabe Pharma's manufacturing and sales operations for 25 days because it was determined a subsidiary of the company fabricated data for Medway Injection 5%, the world's first genetically engineered transgenic human serum albumin, MHLW officials said April 13, and regulatory authorities may level additional administrative penalties against the company
Advertisement

Related Content

Mitsubishi Tanabe's Key Products And M&A Rumors Tempered By Management Issues
Mitsubishi Tanabe's Key Products And M&A Rumors Tempered By Management Issues
Shionogi, Daiichi Sankyo, Mitsubishi Tanabe Await Subsidiary Action For Results: Japanese Earnings Roundup (Part 2 Of 2)
Shionogi, Daiichi Sankyo, Mitsubishi Tanabe Await Subsidiary Action For Results: Japanese Earnings Roundup (Part 2 Of 2)
Mitsubishi Tanabe Domestic Sales Grow 7 Percent
Advertisement
UsernamePublicRestriction

Register

SC074551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel